N-Boc-N-deshydroxyethyl Dasatinib
Synchemia is a leading supplier in pharmaceutical Dasatinib Impurities . Dasatinib (marketed as Sprycel) is a kinase inhibitor primarily used to treat Philadelphia chromosome-positive Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) in adults and children. It treats newly diagnosed cases and patients resistant or intolerant to prior therapy, including imatinib.
N-Boc-N-deshydroxyethyl Dasatinib CAS NO: 1159977-13-5 chemically represented as Tert-butyl 4-(6-((5-((2-chloro-6-methylphenyl)carbamoyl)thiazol-2-yl)amino)-2-methylpyrimidin-4-yl)piperazine-1-carboxylate . It is also known as N-Boc-N-deshydroxyethyl Dasatinib . N-Boc-N-deshydroxyethyl Dasatinib is supplied with comprehensive characterization data, in full compliance with applicable regulatory guidelines. Synchemia is the leading supplier and exporter of N-Boc-N-deshydroxyethyl Dasatinib . All Synchemia products are strictly intended for analytical testing purposes only and not for human use.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-D3774 |
| CAS No | 863127-76-8 |
| Mol.F. | C12H14ClNO2 |
| Mol.Wt. | 239.7g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3775 |
| CAS No | NA |
| Mol.F. | C11H10ClN3OS |
| Mol.Wt. | 267.7g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3776 |
| CAS No | 2518438-16-7 |
| Mol.F. | C13H12ClN3O2S |
| Mol.Wt. | 309.8g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3777 |
| CAS No | NA |
| Mol.F. | C13H9ClF3N3O2S |
| Mol.Wt. | 363.7g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3778 |
| CAS No | 1025814-13-4 |
| Mol.F. | C20H24ClN7O2S |
| Mol.Wt. | 462g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3779 |
| CAS No | 1111850-50-0 |
| Mol.F. | C12H11Cl2N3 |
| Mol.Wt. | 268.1g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3780 |
| CAS No | 2099694-51-4 |
| Mol.F. | C10H7Cl3N4 |
| Mol.Wt. | 289.5g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3781 |
| CAS No | 2099694-52-5 |
| Mol.F. | C21H32N8O3S |
| Mol.Wt. | 476.6g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3782 |
| CAS No | 2468737-80-4 |
| Mol.F. | C27H22Cl2N8O2S2 |
| Mol.Wt. | 625.5g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3783 |
| CAS No | NA |
| Mol.F. | C17H23N5O2S |
| Mol.Wt. | 361.5g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3784 |
| CAS No | 2468737-87-1 |
| Mol.F. | C28H39N9O3S |
| Mol.Wt. | 581.7g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3785 |
| CAS No | 1180525-74-9 |
| Mol.F. | C21H16Cl3N7OS |
| Mol.Wt. | 520.8g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3786 |
| CAS No | NA |
| Mol.F. | C13H10ClN3O4S |
| Mol.Wt. | 339.8g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3787 |
| CAS No | 2167236-23-7 |
| Mol.F. | C6H6N2O4S |
| Mol.Wt. | 202.2g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3788 |
| CAS No | 302964-20-1 |
| Mol.F. | C9H11ClN2O3S |
| Mol.Wt. | 262.7g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-D3789 |
| CAS No | 302964-06-3 |
| Mol.F. | C16H18ClN3O3S |
| Mol.Wt. | 367.8g/mole |
| INV STATUS | CUSTOM SYNTHESIS |